One of the hallmarks in rheumatoid arthritis (RA) is the intense activation of the monocyte-macrophage system. In the present investigation, the modulation of blood monocyte activation was studied with regard to the secretion of cytokines and inflammatory mediators, and to the expression of cytokine receptors. Patients with severe active RA underwent repeated leukapheresis procedures that removed all circulating monocytes. Highly enriched monocyte preparations from the first and third leukapheresis were studied. There were striking differences between these two monocyte populations. Cells obtained from the first leukapheresis constitutively released large amounts of prostaglandin E2 (PGE2), neopterin, interleukin 1, 6 (IL-1I#) and tumor necrosis factor-a (TNF-a). In particular, IL-1jB and neopterin production were further enhanced by stimulation with either interferon-'y (IFN-"y) or TNF-a without a synergistic effect. In contrast, cells derived from the third leukapheresis procedure showed a close to normal activation status with only low levels of cytokine and mediator production as well as a reduced response to cytokine stimulation. The number of the receptors for IFN-y and TNF-a was not changed between first and third leukapheresis. However, TNF-binding capacity was only detectable upon acid treatment of freshly isolated monocytes. A further upregulation was noted upon 24 h in vitro culture, suggesting occupation of membrane receptors and receptor down-regulation by endogenously produced TNF-a. Northern blot analysis of cytokine gene expression was in good correlation with the amount of mediators determined on the protein level. These data indicate that cells of the monocytemacrophage system are already highly activated in the peripheral blood in RA patients with active disease. These cells can be efficiently removed by repeated leukapheresis and are replenished by monocytes that have, with respect to cytokine and mediator production, a considerably lower activation status. (J.
Introduction
The rheumatoid synovium is characterized by the infiltration with activated macrophages which form a major part of the Address reprint requests to Dr. Gerd R. Burmester destructive pannus tissue ( 1, 2) . Not only tissue macrophages, but also blood monocytes show an elevated activation status. These cells already spontaneously produce large amounts of prostanoids and interleukin 1 (IL-1) (3). Furthermore, an increased phagocytic activity of monocytes has been demonstrated (4) . Possible factors leading to monocyte/ macrophage activation are immune complexes, notably those containing rheumatoid factors (5, 6 ), but also several major cytokines have been implicated in the pathogenesis of rheumatoid arthritis such as interferon-y (IFN--y), tumor necrosis factor-a (TNF-a), and colony-stimulating factors (7, 8) .
Neopterin, a pyrimidine derivative, has been found to be elevated in patients suffering from certain types of cancer and viral diseases, but also in individuals with rheumatoid arthritis (RA) (9-1 1 ). Whenever the T lymphocyte-macrophage axis is activated, an increase in neopterin production is to be expected. Neopterins are synthesized in vivo from guanosine triphosphate cyclohydrolase (9) . Macrophages differ from lymphocytes in that they lack enzymes for the synthesis oftetrahydrobiopterin (9, 10), so that they are only able to produce dihydroneopterin. This compound cannot be further metabolized by these cells and can subsequently be easily detected in body fluids and culture supernatants. In vivo levels of neopterin rise whenever cellular immunity is activated. Thus, elevated serum and urine levels of neopterin are highly sensitive markers of the activation of the monocyte/macrophage system.
The objective of the present investigation was to study mechanisms of activation of rheumatoid monocytes as well as to monitor a possible modulation in the course of leukapheresis therapy analyzing the production of inflammatory mediators and cytokines. To this end, patients with severe RA underwent repeated leukapheresis procedures which removed not only circulating lymphocytes, but also all blood monocytes at a given time ( 12, 13) . It has long been puzzling why leukapheresis is an efficient therapy in certain patients long before there is a measurable decrease in the number of peripheral blood lymphocytes ( 14) . We report here that leukapheresis efficiently removes activated monocytes from the blood stream, and that the repopulating cells show a reduced activation status as compared with pretherapy levels. These findings may in part explain the clinical benefits induced by leukapheresis treatment, which has been demonstrated in previous studies.
Methods

Patient population
The total patient population consisted of 10 individuals (5 male and 5 female; mean age 55 yr) with severe RA as diagnosed according to the American College of Rheumatology criteria ( 15 ) . All had highly active disease according to the following test results ( mean±SD): a sedimentation rate of 73±33 mm/h, a C-reactive protein level of 72±27 mg/liter, and a high Ritchie articular index ( 16) of93±25. With the exception of one individual (D.C.), all patients were rheumatoid factor positive with a mean value of 90 IU/ ml in the Waaler-Rose assay. Except for patient D.C., who suffered from a longstanding arthritis, all patients had a disease of recent onset (<5 yr) and had not been treated with remission inducing or immunosuppressive agents. None ofthe patients received steroids. Before each leukapheresis procedure nonsteroidal anti-inflammatory drugs had been withdrawn for at least 12 h. Patients were not treated with antirheumatic agents with a half-life of more than 6 h. In general, three leukapheresis procedures were performed in 2-or 3-d intervals. Materials from the first and third leukapheresis were taken for examination. Immediately at the end of leukapheresis therapy, treatment with remission inducing drugs was started (gold salts or methotrexate). Concomitant clinical assessments revealed a reduction of the mean Ritchie articular index from 93±25 down to 59±14 after the final leukapheresis procedure (P < 0.01, paired t test).
Leukapheresis procedure
Leukapheresis was performed using a Baxter/Travenol cell separating system (CS-2000; Baxter Healthcare Corp., Deerfield, IL) according to the manufacturer's information. As calculated from the differential blood count, 1-2 x 109 monocytes were removed during each run, which was approximately equal to the circulating pool of monocytes ( 17) . There were no differences in absolute monocyte counts before the first and the third leukapheresis (680±231 vs. 689±475 monocytes/,ul). For control experiments, peripheral blood monocytes obtained by a single leukapheresis from healthy donors were used. In two additional patients with RA synovial tissue cells obtained from material derived from joint surgery were investigated.
Cell separation
Peripheral blood cells of leukapheresis material were first applied to a Ficoll-Hypaque gradient to obtain the mononuclear cell fraction. Subsequently, monocytes were enriched by a two step Percoll-Gradient (Percoll, Biochrom, Berlin, FRG) using 51% (d = 0.573 g/ml) Percoll in the first and 48% (d = 0.539 g/ml) Percoll in the second step. The few remaining T cells were removed by an E-rosetting procedure, as described elsewhere ( 18 ) . The purity of the monocyte population was 95% on an average as determined by conventional May-GrunewaldGiemsa staining. There were no significant differences between the purity of monocyte preparations derived from first or third leukapheresis.
Synovial tissue mononuclear cells were eluted from surgical specimens from patients with rheumatoid arthritis undergoing selective joint surgery. Synovial tissue fragments were generated by fine scissors, and mononuclear cells were obtained after DNAse/collagenase digestion by density gradient centrifugation as described previously ( 19) .
Immunofluorescence studies
The evaluation of mononuclear cell populations and the monocyte subset was performed by indirect immunofluorescence using flow cytometry with an Epics Profile cell analyzer (Coulter Corp., Hialeah, FL) (20) . The following reagents were employed: T cell-specific antibodies against the CD3 antigen (OKT3 [ 21] ), anti-B cell, anti-monocyte or anti-HLA-DR reagents (CD75 [22] ; CD14 [23] ; HLA-DR [20] ) used to analyze mononuclear cells, and finally the IFN-y receptor-specific antibody A6C5 (24 
IFN-y and TNF-a binding studies
Binding assays and Scatchard plot analysis ofspecific IFN--y and TNFa binding were performed as described with iodinated recombinant IFN-y and TNF-a, respectively, labeled by the chloramine-T method to high specific radioactivity ,gCi / Ag) under retention ofbioactivity essentially as described ( 18, 27, 28 (Fig. 1) .
In subsequent experiments, this analysis was extended to the production of PGE2 and IL-1O by normal and RA mono- Maximum values of neopterin production are presented.
cytes. As demonstrated in Table I tion with IFN-'y and TNF-a resulted in only a marginally increased production ofPGE2 and neopterin. Although IL-I production was stimulated, the levels reached were well below those of unstimulated cells from the first leukapheresis material.
Similar data on the IL-I production by RA monocytes were obtained in two additional RA patients. Again, a marked reduction of IL-I secretion was seen (patients 3 and 4, Table  IIA ). In a separate patient, IL-I levels were determined by the LAF bioassay. Bioactive IL-I was secreted in significantly higher amounts in material derived from the first vs. the third leukapheresis at all time points of monocyte cultures investigated confirming the ELISA findings observed in the other patients (data not shown). As demonstrated in Table IIA , repeated leukapheresis resulted in a reduction of bioactive IL-I down to 17% of the initial levels.
In additional experiments, monocytes derived from three RA patients were phenotypically characterized by determining the expression ofthe CD 14 and HLA-DR antigens. These studies showed a small, but consistant decrease in the expression of both surface molecules in the course of leukapheresis therapy Northern blot analyses. Monocytes obtained from leukapheresis material derived from normal blood donors and an additional highly active RA patient were used for total RNA preparation and Northern blot analysis of TNF-a and IL-1(3 gene expression. A y-actin probe was used as a control to determine mRNA quantity. In parallel, RNA from the promyelocytic cell line HL-60 and from granulocytes obtained from the synovial fluid of an additional RA patient served as further controls. As shown in Fig. 3 and Table IIB , IL-1( ( 1.7 kb) and TNF-a ( 1.6 kb) mRNA levels were increased in RA monocytes derived from the first leukapheresis. In monocytes from the third leukapheresis, the IL-1O and TNF-a mRNA levels were highly reduced as determined by Laser scanning densitometry (IL-13 down to 22%, and TNF-a down to 11.2% of the first leukapheresis levels after adjustment for mRNA levels as calculated using the y-actin signal). They were thus comparable to those of normal donors (Table IIB) . In RNA preparations from the HL-60 cell line only small amounts of IL-13 mRNA were found, and no signal for TNF-a was revealed. In granulocytes neither IL-1 O nor TNF-a mRNAs were detectable.
Expression ofthe receptorsfor IFN-'y and TNF-a on monocytes. Cytokines initiate their various bioactivities by high affinity binding to specific cell surface receptors (31 ). Our previous studies had shown that in PBMC the IFN-'y receptor is subjected to heterologous down-regulation by granulocyte/ macrophage colony-stimulating factor ( 18) . In contrast to the constitutively expressed IFN--y receptor, expression of TNF receptors by peripheral blood lymphocytes has been shown to be activation dependent (32). The expression of TNF-receptors in peripheral blood monocytes at various stages of in vivo activation has not been studied so far. We have here investigated IFN-y and TNF-a receptor expression in monocytes and asked whether receptor levels were influenced by repeated leukapheresis. Sufficient material was available from two patients with RA. Scatchard plot analyses and immunofluorescence studies with receptor-specific antibodies revealed no changes in IFN-'y receptor expression in both patients between the first and third leukapheresis (Table III) . Similarly, specific TNF-binding capacity, determined in one patient after the first and third leukapheresis was not changed. Interestingly, TNF receptors (500 per cell) could only be revealed upon acid wash of monocytes, releasing potentially receptor-bound TNF-a. Moreover, upon 24 h in vitro culture without intentional stimulation, a two-to fivefold increased TNF binding capacity was revealed in both patients (Table III) suggesting up-regulation of TNF receptor expression.
Discussion
In RA the monocyte/macrophage system is strongly activated as documented by an increased production of inflammatory mediators (33) (34) (35) , enhanced expression of Fc receptors (5) and an augmented phagocytic activity ofmonocytes (4) . In the present investigation we studied the production of inflammatory mediators by monocytes and the possible modulation of their activity in patients suffering from severe RA. The following major points emerged from this study: (a) Monocytes from RA patients with active disease spontaneously produce large
Modulation ofMonocyte Activation in Rheumatoid Arthritis by Leukapheresis 865 . Production of PGE2 (ng/ml), IL-1: (pg/ml), neopterin (nmol/l), and TNF-a (pg/ml) by peripheral blood monocytes (1 X 106/ml) from two RA patients (above: patient with seropositive disease; opposite page: patient with seronegative disease). Cells were obtained from the first and the third leukapheresis run and cultured in various concentrations of recombinant IFN--y and/or TNF-a ranging from 1 to 100 U/ml or medium alone for [1] [2] [3] [4] [5] These findings strongly support the hypothesis that the monocyte-macrophage system plays a pivotal role in the pathogenesis of rheumatoid arthritis. We deliberately selected highly active patients for investigation to presumably obtain maximum levels of inflammatory markers. None of these patients was treated with steroids or immunosuppressive or remissioninducing drugs at the time ofstudy, and nonsteroidal drugs had been discontinued in a time period which was ethically justifiable.
One particularly useful marker indicative of activation of the mononuclear phagocyte system proved to be neopterin. As mentioned above, in the human system this molecule is exclusively produced by monocytes and macrophages. This was also evident in our study where neither synovial tissue fibroblasts, endothelial cells, nor lymphocytes ofblood or tissue origin produced detectable levels of neopterin (data not shown). Comprehensive studies by Wachter, Huber, and other investigators had already shown elevated levels in the serum, urin and synovial fluid in RA, strongly correlated to disease activity (36) (37) (38) (39) (40) Table IIB. Our study also raises the question ofwhat signals are responsible for monocyte activation in RA. One of the patients analyzed suffered from severe erosive RA, but had no detectable rheumatoid factors or immune complexes (Clq binding and polyethylene glycol precipitation assay). Thus, at least in this patient it appears unlikely that these humoral factors are by themselves responsible for monocyte activation, which otherwise has been well substantiated (6) . In a regular activation pathway, e.g., in infectious disease situations (45, 46) , monocytes receive their stimulatory signals from T cells. However, while expression of phenotypical activation markers of T cells 
